The US District Court for the District of New Jersey has granted summary judgment in Israel’s Teva Pharmaceutical Industries favor on the issue of non-infringement with regard to Organon's Remeron Patent. Mirtazapine is the generic version of Remeron, a monotherapy treatment for depression produced by Organon, a unit of Akzo Nobel.
“In January 2002, Teva received tentative approval of its ANDA for mirtazapine. This court decision should now allow the FDA to proceed to grant us final approval of our ANDA in the near future. We believe that we will be entitled to 180 days of exclusivity for this product, " said President and CEO of Teva Pharmaceutical Israel Makov.
Teva is among the top 35 pharmaceutical companies and among the largest generic pharmaceutical companies in the world. Over 80 percent of Teva's sales are in North America and Europe. The company develops, manufactures and markets generic and innovative human pharmaceuticals and active pharmaceutical ingredients.¸— (menareport.com
© 2002 Mena Report (www.menareport.com)
